The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Remifentanil 2 mg powder for concentrate for solution for injection or infusion

2 milligram(s) Powder for concentrate for solution for injection/infusion

Fresenius Kabi Deutschland GmbHPA2059/056/002

Main Information

Trade NameRemifentanil 2 mg powder for concentrate for solution for injection or infusion
Active SubstancesRemifentanil
Strength2 milligram(s)
Dosage FormPowder for concentrate for solution for injection/infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/056/002

Group Information

ATC CodeN01AH Opioid anesthetics
N01AH06 remifentanil

Status

Authorised/WithdrawnAuthorised
Licence Issued01/10/2010
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back